Company intelligence / Profile preview

Tusk Therapeutics

Stevenage, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Tusk Therapeutics developed novel immune-modulating antibodies for cancer, including non-IL-2 blocking anti-CD25 that depletes regulatory T cells and preserves IL-2 cytokine signaling in effector cells. Preclinical proof-of-concept data demonstrated potent anti-tumor responses, presented at AACR 2018. The anti-CD38 program aims at both hematologic and solid tumors

Therapeutic areas: Oncology
Modalities: AntibodyMonoclonal antibody
Industry: Biotech

Partnerships

Cancer Research UKUniversity College London (UCL)

Beyond the preview

Go deeper on Tusk Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tusk Therapeutics.

Explore the full profile